ATAtai Life Sciences N.V. ATAI · NASDAQ
$7.35 +0.68% (+$0.05)
- Market cap
- $2.72B
- Enterprise value
- $2.55B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 607.9x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -61.3%
- Gross margin
- 86.3%
- Net margin
- -14,938.4%
- Dividend yield
- 91.84%
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.55
- Free float
- 54.2%
About the company
Atai Life Sciences N.V. (ATAI) is a biotechnology company focused on research and development of novel therapeutic approaches in the field of mental health and psychiatric disorders. The company focuses on innovative therapies and drugs that have the potential to treat or improve the lives of people suffering from various mental illnesses, including depression, anxiety, post-traumatic stress disorder, addictions, and other disorders. Atai Life Sciences actively collaborates with other research institutions and biotechnology companies and invests in projects with the hope of discovering new treatment options. Their goal is to bring new drugs and therapies to the market that can make a significant difference for patients with mental disorders. Atai Life Sciences N.V. (ATAI) shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company focusing on innovative therapeutic approaches in the field of mental health.
Sector
Healthcare
Industry
Biotechnology
CEO
Srinivas G. Rao
Employees
99
Headquarters
New York
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 160% a year over the last 3 years.
- What to watch: Analysts expect revenue to fall by 47% this fiscal year.
- What to watch: It missed profit estimates 4 times in the last 8 quarters.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $168.8M against $4.29M.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number